DRMA Dermata Therapeutics Inc Total Asset Value of Company

DRMA (Dermata) - company brandmark

Dermata Therapeutics (DRMA) is implementing automated systems for molecule analysis and the processing of trial data sets. Since the business is at a pre-commercial stage and focused on testing, there is no revenue or free cash flow. This chart shows that the total assets amount to 5.98. Dermata Therapeutics (DRMA) aims to capture the rosacea and acne drug niche by utilizing innovative drug delivery methods.

DRMA (Dermata Therapeutics) Company Total Assets history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Dermata (DRMA)

- market value and analyst target forecast:
Stock Price dermatarx.com|DRMA - Price Target Chart
- market capitalization data:
Market Valuation Dermata Corp|DRMA - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Dermata Therapeutics|DRMA - Book Capitalization|Market Capitalization to Book Value Ratio dermatarx.com|DRMA - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Dermata Therapeutics|DRMA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Dermata Corp|DRMA - Company Aggregate Debts|Debts to Book Capitalization Dermata Corp|DRMA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Dermata Therapeutics|Interim Coverage Ratio dermatarx.com
- net income and valuation multiples indicators:
DRMA - Company Net Income
Fundamental valuation:Dermata Therapeutics
Manufactured products of Dermata Therapeutics

In an oversaturated dermatological products market, the expansion of Dermata Therapeutics (DRMA) via microneedle innovations requires significant resources; therefore, a reverse valuation of total asset value calculated through ROA without time lags allows for tracking the actual scale of control over property and capital, helping investors distinguish organic growth of the production base from the hidden accumulation of risky liabilities.

Key competitors

krystalbio.com (KRYS) - Company Total Assets|Aggregate Company Assets Apogee Therapeutics, Inc.|Arcutis - Total Asset Value of Company|Company Total Assets VCEL|ORKA (Oruka Pharma) - Aggregate Asset Value|Company Total Assets SMTI (Sanara MedTech)|Company Total Assets DBV Tech DBVT|SLSN - Aggregate Company Assets|Aggregate Asset Value DERM (Journey Medical)|Forte Biosciences, Inc (FBRX) - Aggregate Company Assets|Cumulative Company Assets Empro Corporation|SLGL (Sol-Gel Technologies) - Company Total Assets|Company Total Assets Revive Pro Care|Cumulative Company Assets MDCX (Medicus Pharma)|VRCA (verrica.com) - Aggregate Asset Value|Aggregate Company Assets Hoth Therapeutics HOTH|Company Total Asset Base Biofrontera, Inc. (BFRI)|VYNE - Aggregate Company Assets|SNOA - Company Total Assets|QNRX: Company Total Assets|AZTR - Company Total Asset Base|Aggregate Company Assets Elevai Skincare|Total Business Assets RVNC (Revance Therapeutics Inc)